• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

炎症性肠病患者使用生物治疗的感染风险。

Infection Risk With Biologic Therapy in Patients With Inflammatory Bowel Disease.

机构信息

Department of Gastroenterology, University of Ghent, Ghent, Belgium.

Department of Gastroenterology, Ljubljana University Medical Centre, Ljubljana, Slovenia.

出版信息

Clin Pharmacol Ther. 2017 Oct;102(4):633-641. doi: 10.1002/cpt.791. Epub 2017 Aug 16.

DOI:10.1002/cpt.791
PMID:28699217
Abstract

The development of biologic drugs revolutionized the management of inflammatory bowel diseases: Crohn's disease and ulcerative colitis. However, while their efficacy has been well established, it remains uncertain to what extent biologic treatments may be associated with important safety risks, such as serious infections, opportunistic infections, or tuberculosis reactivation. Herein, we review and discuss the current evidence on the infection risk associated with biologic therapy in patients with inflammatory bowel disease (IBD).

摘要

生物制剂的发展彻底改变了炎症性肠病（克罗恩病和溃疡性结肠炎）的治疗模式。然而，尽管其疗效已得到充分证实，但生物治疗可能会带来严重感染、机会性感染或结核再激活等重要安全风险的程度仍不确定。在此，我们回顾并讨论了目前关于炎症性肠病（IBD）患者接受生物治疗相关感染风险的证据。

相似文献

1
Infection Risk With Biologic Therapy in Patients With Inflammatory Bowel Disease.炎症性肠病患者使用生物治疗的感染风险。
Clin Pharmacol Ther. 2017 Oct;102(4):633-641. doi: 10.1002/cpt.791. Epub 2017 Aug 16.
2
Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis.生物疗法与炎症性肠病患者感染和恶性肿瘤风险：系统评价和网络荟萃分析。
Clin Gastroenterol Hepatol. 2016 Oct;14(10):1385-1397.e10. doi: 10.1016/j.cgh.2016.04.039. Epub 2016 May 14.
3
De-escalation of medical therapy in inflammatory bowel disease.炎症性肠病的医疗治疗降级。
Curr Opin Pharmacol. 2020 Dec;55:73-81. doi: 10.1016/j.coph.2020.09.014. Epub 2020 Nov 5.
4
Treatment with biologic therapies and the risk of cancer in patients with IBD.炎症性肠病患者使用生物疗法治疗与癌症风险
Nat Clin Pract Gastroenterol Hepatol. 2007 Feb;4(2):78-91. doi: 10.1038/ncpgasthep0695.
5
Methods to avoid infections in patients with inflammatory bowel disease.炎症性肠病患者避免感染的方法。
Inflamm Bowel Dis. 2005 Jul;11(7):685-95. doi: 10.1097/01.mib.0000160742.91602.b7.
6
Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.英夫利昔单抗和其他抗肿瘤坏死因子 α 治疗药物治疗炎症性肠病。
BioDrugs. 2010 Dec 14;24 Suppl 1:3-14. doi: 10.2165/11586290-000000000-00000.
7
Diagnostic and vaccine strategies to prevent infections in patients with inflammatory bowel disease.诊断和疫苗策略以预防炎症性肠病患者的感染。
J Infect. 2017 May;74(5):433-441. doi: 10.1016/j.jinf.2017.02.009. Epub 2017 Mar 2.
8
Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease.高龄是炎症性肠病患者接受抗肿瘤坏死因子治疗后发生严重感染和死亡的独立危险因素。
Clin Gastroenterol Hepatol. 2011 Jan;9(1):30-5. doi: 10.1016/j.cgh.2010.09.026. Epub 2010 Oct 15.
9
Tuberculosis in the age of biologic therapy.生物治疗时代的结核病
J Am Acad Dermatol. 2008 Sep;59(3):363-80; quiz 382-4. doi: 10.1016/j.jaad.2008.05.033.
10
Safety issues with biological therapies for inflammatory bowel disease.炎症性肠病生物疗法的安全性问题。
Curr Opin Gastroenterol. 2006 Jul;22(4):370-6. doi: 10.1097/01.mog.0000231810.87901.e8.

引用本文的文献

1
Evidence for a Modulatory Effect of a 12-Week Pomegranate Juice Intervention on the Transcriptional Response in Inflammatory Bowel Disease Patients Reducing Fecal Calprotectin Levels: Findings From a Proof-of-Principle Study.一项关于石榴汁干预12周对炎症性肠病患者转录反应及降低粪便钙卫蛋白水平的调节作用的证据：一项原理验证研究的结果
Mol Nutr Food Res. 2025 Aug;69(15):e70067. doi: 10.1002/mnfr.70067. Epub 2025 Apr 21.
2
Development and Validation of a Remote Monitoring Tool for Assessment of Mild, Moderate, and Severe Infections in Inflammatory Bowel Disease.开发和验证一种远程监测工具，用于评估炎症性肠病中的轻度、中度和重度感染。
J Crohns Colitis. 2023 Jul 5;17(7):1079-1088. doi: 10.1093/ecco-jcc/jjad023.
3
Transcriptomic analyses of treatment-naïve pediatric ulcerative colitis patients and exploration of underlying disease pathogenesis.
治疗初发小儿溃疡性结肠炎患者的转录组学分析及潜在疾病发病机制的探索。
J Transl Med. 2023 Jan 16;21(1):30. doi: 10.1186/s12967-023-03881-6.
4
Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis.生物类似药与原研英夫利昔单抗治疗炎症性肠病患者的疗效和安全性：真实世界队列分析。
Indian J Gastroenterol. 2022 Oct;41(5):446-455. doi: 10.1007/s12664-022-01252-5. Epub 2022 Nov 15.
5
Subcutaneous Infliximab [CT-P13], a True Biologic 2.0. Real Clinical Practice Multicentre Study.皮下注射英夫利昔单抗[CT-P13]，一种真正的生物制剂2.0。真实临床实践多中心研究。
Biomedicines. 2022 Aug 30;10(9):2130. doi: 10.3390/biomedicines10092130.
6
Absence of Oral Opportunistic Infections in Patients with Inflammatory Bowel Disease Receiving Anti-TNF-α and Anti-Integrin-αβ Therapy.接受抗TNF-α和抗整合素-αβ治疗的炎症性肠病患者未出现口腔机会性感染
Dent J (Basel). 2022 Feb 23;10(3):32. doi: 10.3390/dj10030032.
7
Severe COVID-19 in inflammatory bowel disease patients in a population-based setting.基于人群的炎症性肠病患者中严重 COVID-19 的情况。
PLoS One. 2021 Oct 5;16(10):e0258271. doi: 10.1371/journal.pone.0258271. eCollection 2021.
8
Life expectancy and health-adjusted life expectancy in people with inflammatory bowel disease.炎症性肠病患者的预期寿命和健康调整预期寿命。
CMAJ. 2020 Nov 9;192(45):E1394-E1402. doi: 10.1503/cmaj.190976.
9
Gastrointestinal Disorders and Metabolic Syndrome: Dysbiosis as a Key Link and Common Bioactive Dietary Components Useful for their Treatment.胃肠道疾病与代谢综合征：肠道菌群失调作为关键联系及用于治疗的常见生物活性膳食成分
Int J Mol Sci. 2020 Jul 13;21(14):4929. doi: 10.3390/ijms21144929.
10
Serious and Opportunistic Infections in Elderly Patients With Inflammatory Bowel Disease.老年炎症性肠病患者的严重及机会性感染
Gastroenterol Hepatol (N Y). 2019 Nov;15(11):593-605.